Free tool
FAERS Monitor: Kyzatrex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213953 or its brand name (Kyzatrex, Testosterone Undecanoate). Reports on generic versions are filed under their own applications.
Reports
259
Serious
209
81% of reports
Hospitalization
94
Death reported
20
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use29
- drug abuse13
- asthma10
- atrial fibrillation10
- erectile dysfunction9
- fatigue9
- weight decreased9
- duodenal ulcer8
- erosive duodenitis8
- faeces discoloured8
- headache8
- hypertension8
- pneumonia haemophilus8
- polycythaemia8
- product use in unapproved indication8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 22 |
| 2019 | 8 |
| 2020 | 9 |
| 2021 | 14 |
| 2022 | 11 |
| 2023 | 19 |
| 2024 | 24 |
| 2025 | 61 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,900 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pneumonia haemophilusSignal | 8 | 1360.5 | 683.7 | 9,394 |
| erosive duodenitisSignal | 8 | 821.1 | 413.6 | 5,701 |
| polycythaemiaSignal | 8 | 316.1 | 159.6 | 2,200 |
| duodenal ulcerSignal | 8 | 92.2 | 46.6 | 633 |
| faeces discolouredSignal | 8 | 30.0 | 15.2 | 196 |
| erectile dysfunctionSignal | 9 | 28.5 | 15.0 | 212 |
| drug abuseSignal | 13 | 12.7 | 7.5 | 129 |
| atrial fibrillationSignal | 10 | 8.3 | 4.5 | 58 |
| asthmaSignal | 10 | 7.2 | 3.9 | 47 |
| hypertensionSignal | 8 | 3.1 | 1.6 | 9 |
| off label useSignal | 29 | 2.7 | 1.9 | 30 |
| product use in unapproved indicationSignal | 8 | 2.6 | 1.3 | 7 |
| weight decreasedSignal | 9 | 2.6 | 1.4 | 8 |
| headache | 8 | 1.0 | 0.5 | 0 |
| fatigue | 9 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.